^
    6d
    Converting HR+ Breast Cancer Into an Individualized Vaccine (clinicaltrials.gov)
    P2, N=100, Recruiting, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Mobista (CDX-301)
    27d
    1B-22-2: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)
    1m
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed
    Trial completion
    |
    IMM-101
    2ms
    GEN001-201: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    2ms
    KEYNOTE-D86: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • GEN-001
    2ms
    CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | N=15 --> 9 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
    4ms
    MATCHPOINT: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    Keytruda (pembrolizumab)
    4ms
    NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
    P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
    5ms
    LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
    P2, N=27, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed | N=56 --> 27
    Trial completion • Enrollment change • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    lerapolturev (PVS-RIPO)
    5ms
    Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov)
    P1, N=23, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    5ms
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Orionis Biosciences Inc | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    ORB-011
    6ms
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    IMM-101